ReviewMolecular psychiatry2023
The genetic basis of major depressive disorder.
Review in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 5 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling.Nature genetics · 2026Pooled it
- Transcranial direct current stimulation combined with cognitive-behavioral interventions for depressive disorders: a systematic review and meta-analysis of sham-controlled randomized trials.Frontiers in psychiatry · 2026Pooled it
- Unraveling the associations between voice pitch and major depressive disorder: a multisite genetic study.Molecular psychiatry · 2025Pooled it
- Machine learning approaches in the therapeutic outcome prediction in major depressive disorder: a systematic review.Frontiers in psychiatry · 2025Pooled it
- Developing a translational research framework for MDD: combining biomolecular mechanisms with a spiraling risk factor model.Frontiers in psychiatry · 2024Pooled it
- Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis.International journal of molecular sciences · 2023Trial
- From gut to brain: data-driven evidence suggests causal contribution of gut-microbiota to major depressive disorder in humans.Gut microbes · 2026Article
- Neuropsychiatry genetics in Africa.Nature communications · 2026Review
- Genetics of major depressive disorder in a homogeneous population with uniform phenotyping.Molecular psychiatry · 2026Article
- The Dangerous Liaison Between Depression and Cardiovascular Disease: A Narrative Review of Epidemiology, Mechanisms, and Clinical Management.Journal of clinical medicine · 2026Review
- Dissecting pleiotropy between major depressive disorder and physical disease comorbidities.Nature genetics · 2026Article
- Potential for Genomics to Help Guide Preventive Strategies in Psychiatry.JAMA psychiatry · 2026Article
- Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder.Molecular psychiatry · 2026Article
- Histone Modifications in Psychiatry: From Canonical Marks to Neurotransmitter-Mediated Epigenetic Signatures.Alpha psychiatry · 2026Review
- Persistence of loneliness and low self-esteem from adolescence through age 60 in the United States: results from the Monitoring the Future Panel Study.Social psychiatry and psychiatric epidemiology · 2026Article
- Volatile organic compound exposure and depression risk: insights from individual, mixture, and sex-stratified analyses.BMC public health · 2026Article
- Can Psychiatric Genetics Advance Without Incorporating a Life Course Perspective?Biological psychiatry · 2026Review
- Biological aging mediates the association between cancer and depression risk: findings from NHANES.Journal of cancer survivorship : research and practice · 2026Article
- Astrocyte fatty acid metabolism as a driver of risk for major depressive disorder.Nature communications · 2026Article
- Transcription factors Lef1 and Rest stimulate recovery from depressive states.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The genetic dissection of major depressive disorder (MDD) ranks as one of the success stories of psychiatric genetics, with genome-wide association studies (GWAS) identifying 178 genetic risk loci and proposing more than 200 candidate genes. However, the GWAS results derive from the analysis of cohorts in which most cases are diagnosed by minimal phenotyping, a method that has low specificity. I review data indicating that there is a large genetic component unique to MDD that remains inaccessible to minimal phenotyping strategies and that the majority of genetic risk loci identified with minimal phenotyping approaches are unlikely to be MDD risk loci. I show that inventive uses of biobank data, novel imputation methods, combined with more interviewer diagnosed cases, can identify loci that contribute to the episodic severe shifts of mood, and neurovegetative and cognitive changes that are central to MDD. Furthermore, new theories about the nature and causes of MDD, drawing upon advances in neuroscience and psychology, can provide handles on how best to interpret and exploit genetic mapping results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.